Seed, scaffold and signal in cartilage repair
Cartilage has no blood supply and so cannot self-repair: there is no circulation to deliver repair cells to an injury. An effective single-session treatment places ear cartilage cells at the defect, holds them with a collagen scaffold, and supplies growth signals via platelet-rich fibrin—addressing all three biological requirements simultaneously.
Why cartilage repair needs three distinct biological roles
Cartilage is one of the few tissues in the body with no blood supply of its own. That single fact explains why a damaged joint so rarely recovers unaided: without blood vessels, there are no circulating repair cells to reach the injury site, and without repair cells, the void simply stays. The body's default response — filling the gap with fibrous scar tissue — is structurally weak and rarely durable.
Getting living cells into that void is only the first step. Injected cells are slippery; in a fluid-filled joint, they wash away from the defect within minutes unless something holds them in place. A scaffold — a physical structure lodged at the site — solves this retention problem, giving transplanted cells a stable home in which to settle and build.
Even well-retained cells still need instruction. Placed in an unfamiliar environment, they require biological signals — growth factors — to behave appropriately, to proliferate, and to lay down the right kind of matrix.
Three failure modes, then: no cells, no retention, no signal. An effective repair strategy must address all three simultaneously, at the point of care, without adding the burden of a second operation. That is the logic the seed-scaffold-signal framework is designed to answer.
The seed: why ear cartilage is used, not joint cartilage
The obvious question is: why take cartilage from the ear to repair a joint? The answer lies not in anatomy but in developmental biology.
Joint cartilage forms from mesoderm — the middle embryonic layer that builds bones, muscles and most of the body's structural tissues. Ear cartilage takes a different route entirely: it originates from the neural crest, the cell population responsible for much of the face and skull. This is not a minor anatomical footnote. It is a fundamental difference in biological identity with practical consequences for repair.
Neural-crest-derived chondrocytes are described as HOX-gene-negative. HOX genes act like a postcode system for the body: they encode each cell's positional address, locking it into a specific anatomical role. Articular chondrocytes carry that address. Ear chondrocytes do not — they are, in effect, developmentally uncommitted. Researchers in Basel demonstrated this experimentally: when adult human neural-crest cartilage cells were transplanted into a joint environment, they read their new surroundings and adopted joint-appropriate behaviour rather than persisting as ear cells. The flexibility is not theoretical; it has been observed.
Beyond adaptability, neural-crest chondrocytes have been reported to outperform their articular counterparts in several measurable ways: higher and more reproducible chondrogenic potential, stronger proliferation, more stable chondrogenic differentiation, and greater resistance to dedifferentiation — the tendency of expanded cartilage cells to drift towards a fibroblast-like state.
The harvest site is the concha, the small bowl at the centre of the ear. ENT and plastic surgeons have used concha cartilage to rebuild noses for decades, establishing a long and well-documented safety record at this donor location.
Published human studies provide component-level support for this approach. Marcarelli et al. (JCM, 2021) reported improved quality of life and MRI cartilage thickness at three years in knee chondropathy patients; Tsoukas et al. (Bioengineering, 2023) recorded reduced pain and improved function after a single intra-articular application in early-to-moderate knee osteoarthritis; and Helito et al. (Bioengineering, 2024) reported pilot improvement data in a 12-month series.
The scaffold: how the collagen matrix keeps cells at the repair site
Even the right cells, sourced from the right donor site, cannot contribute to repair if they do not stay where they are needed. A fluid-filled joint is an unforgiving environment for a freshly injected cell suspension: without a physical anchor, micrografts disperse from the defect within minutes and the opportunity is lost.
ChondroFiller addresses this retention problem directly. Manufactured by meidrix biomedicals GmbH of Esslingen, Germany — with the injectable liquid form CE-marked since 2013 — it is a cell-free native type I collagen matrix that arrives at the defect as a liquid and then polymerises in situ at body temperature, forming a three-dimensional collagen mesh. The micrografts are held within that mesh at the repair site, in a physical home they can populate and, over time, remodel.
The way the collagen is extracted matters. Most collagen preparations are digested with pepsin, which strips away the telopeptide end-caps of the triple helix and with them the capacity for authentic cross-linking. ChondroFiller uses a non-enzymatic, weak-acid process that leaves those telopeptides intact, allowing the matrix to assemble in a way that more closely mirrors native extracellular matrix rather than acting as an inert filler.
That biological character distinguishes it from the two alternatives most often compared in clinical practice. Hyaluronic acid is principally a lubricant; the joint clears it within weeks. Synthetic permanent gels provide cushion but cannot be integrated or remodelled by resident cells. ChondroFiller is designed to be gradually populated and replaced as repair progresses.
More than 20,000 implantations across over a decade of documented clinical use underpin its track record. Weninger et al. (2025) reported outcomes in Grade IV — end-stage — knees using a scaffold-plus-cells pairing, with MOCART scores between 70 and 87, providing direct component-pair evidence for this approach in demanding conditions.
The signal: what platelet-rich fibrin tells the repair cells to do
Placing living cells into an inert medium — a saline solution — keeps them viable but says nothing to them. Saline provides no instruction, no biochemical context, no encouragement to form tissue. The third component of NanoACi replaces that silence with a biologically active signal drawn from the patient's own body.
Arthrozheal is autologous platelet-rich fibrin (PRF): prepared from a venous blood draw taken at the same sitting, the sample is centrifuged to concentrate the patient's own platelets and leukocytes within a fibrin matrix. Because it derives directly from the patient's blood rather than from any manufactured product, PRF is classified by the FDA under blood draw/haematology product code KST and is 510(k) exempt — it is an autologous blood preparation, not a drug.
The difference from standard platelet-rich plasma (PRP) is one of release kinetics. PRP delivers growth factors in a single burst at the point of injection. PRF embeds those factors within the fibrin matrix itself, so they are released gradually as the matrix is remodelled — providing sustained biological signalling over the course of the repair process rather than a one-time dose.
Lundquist et al. (2008) and Ågren et al. (Vox Sanguinis, 2014) characterised this growth-factor profile, documenting fibroblast proliferation and type I collagen synthesis as downstream effects. Component evidence from Peset (2020) documented PRF application specifically in knee osteoarthritis. In the NanoACi protocol, Arthrozheal serves a dual purpose: it is both the carrier medium in which the micrografts are suspended during delivery and the sustained signalling environment into which those cells are introduced — replacing an inert vehicle with one that actively supports the repair process from the moment of injection.
How the three parts come together in a single planned session
The sequence matters as much as the components. On the day of the procedure, a small sample of cartilage is harvested from the concha under local anaesthetic — the same donor site that ENT and plastic surgeons have used in nasal reconstruction for decades. That sample is mechanically processed at point of care into micrografts: no enzymes, no laboratory send-off, no interval of weeks while cells are cultured. The micrografts are then combined with the collagen matrix and Arthrozheal PRF — the scaffold providing physical retention, the PRF replacing an inert saline suspension with a biologically active medium — and the preparation is delivered by needle to the defect site under image guidance.
From harvest to delivery, every step takes place in one planned sitting, with no second surgical admission, no laboratory gap and no arthroscope. This is the practical meaning of taking the operation out of cartilage surgery: the biological work remains; the procedural architecture around it — the second hospital visit, the cell culture, the arthroscopy port — does not.
Needle delivery is the access route, not the whole procedure. The sitting is preceded by specialist imaging review and case selection; it is followed by a structured post-procedure monitoring programme. NanoACi represents a non-arthroscopic lane for suitable patients — alongside, not above, conventional ACI, MACI or open surgery. Alignment, mechanical instability, defect characteristics, diagnosis and a patient's own goals all bear on that judgement, and individual suitability is determined through clinical assessment rather than any general rule.
What the evidence covers and what is still being measured
Building a rationally assembled technique from evidenced components is the standard trajectory in specialist clinical practice — not a shortcut, and not an apology. The three parts of NanoACi each carry published biological and clinical support, and the scaffold-plus-cells pairing has been evaluated in Grade IV knees specifically. What has not yet been done is a randomised controlled trial of the exact three-part combination — seed, scaffold and signal used together — and that distinction matters.
The NanoACi 100 prospective series is the active vehicle for generating that combined-protocol data: 100 consecutive patients, structured follow-up, outcomes measured from the beginning. Results from this study are not yet published. Until they are, the appropriate description of the full three-part protocol is that it is rationally designed from evidenced parts, with component and pairing data providing the biological foundation and prospective combined outcomes still in development.
For clinicians and patients, the practical implication is straightforward: the underlying biology is supported, the components are individually established, and the rigorous work of quantifying combined outcomes in a defined patient population is under way. That is a meaningful — and measurable — starting point. Individual suitability depends on the specific picture: defect grade, joint alignment, symptom history, imaging findings, and goals that only a clinical assessment can weigh.
